Results 161 to 170 of about 112,287,737 (220)

ErbB family receptor dimerization dynamics and dysregulation via long-term single-molecule imaging. [PDF]

Cell
Ma K, Ma X, Shida JF, Niu Z, Lin YK, Mandal S, Dobbins A, Golomb L, Eck MJ, Greulich H, Meyerson M, Peng CS.   +11 more
europepmc   +1 more source

Neuroepithelial reprogramming and ERBB vulnerability in canine acanthomatous ameloblastoma. [PDF]

Mol Ther Oncol
Stephanou A, Shui B, Mische D, Byron M, Katt WP, Chan M, Grenier JK, De Vlaminck I, Duhamel GE, Gujral TS, Sethupathy P, Peralta S.   +11 more
europepmc   +1 more source

Correction: Integrated analysis of the aqueous humor microbiome and lens capsule transcriptome in high myopia cataract: a pilot study. [PDF]

Front Med (Lausanne)
Qiu Y, Cai W, Xie Z, Li C, Yang F, Qian Y, Song J, Zheng T.   +7 more
europepmc   +1 more source

Metachronous bilateral ovarian metastasis with spontaneous rupture following curative resection of stage T4a colon cancer: a case report and literature review. [PDF]

Front Oncol
Zheng Y, Zhang Z.
europepmc   +1 more source

Signal transduction in c-erbB-2 pathway

, 1992
openaire   +1 more source

HER1-HER4 expression and co-expression in advanced urothelial carcinoma. [PDF]

ESMO Open
Coca Membribes S, Berney DM, Beltran L, Nally E, Jackson-Spence F, Szabados B, Mariathasan S, Powles T, Ackerman C.   +8 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

C-erbB-2 Immunostaining in Laryngeal Cancer

Acta Oto-Laryngologica, 1999
Tumour progression is strongly associated with a series of specific genetic changes in protooncogenes and tumour suppressor genes. One of the potential factors involved in tumorogenesis of squamous cell carcinomas is protooncogene c-erbB-2 (also known as neu or HER2). The authors analysed the expression of c-erbB-2 oncoprotein in 154 cases of laryngeal
T, Krecicki, M, Jeleń, M, Zalesska-Krecicka   +2 more
openaire   +3 more sources

Identity of BCA200 and c-erbB-2 indicated by reactivity of monoclonal antibodies with recombinant c-erbB-2

Molecular Immunology, 1991
BCA200 has been described as a 200,000 Mr monomeric cell surface glycoprotein associated with human breast cancer. Since the physical properties and cellular distribution of BCA200 resemble those of c-erbB-2, antibodies to BCA200 were tested for the ability to bind a recombinant protein containing the c-erbB-2 extracellular domain (erbB-2 ECD).
D B, Ring, R, Clark, A, Saxena
openaire   +2 more sources